Wells Fargo & Company MN Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Wells Fargo & Company MN grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 298.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 458,321 shares of the company's stock after purchasing an additional 343,304 shares during the quarter. Wells Fargo & Company MN owned approximately 0.12% of Recursion Pharmaceuticals worth $3,098,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after purchasing an additional 9,737,196 shares during the period. Norges Bank bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $23,429,000. Geode Capital Management LLC grew its position in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company's stock worth $35,803,000 after buying an additional 656,003 shares during the period. Institute for Wealth Management LLC. purchased a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $3,928,000. Finally, Platinum Investment Management Ltd. increased its position in Recursion Pharmaceuticals by 293.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company's stock valued at $4,955,000 after buying an additional 546,929 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Down 0.9 %

NASDAQ RXRX opened at $5.58 on Thursday. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a 50 day moving average price of $6.40 and a 200-day moving average price of $6.78. The company has a market capitalization of $2.24 billion, a P/E ratio of -3.65 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was down 57.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.42) earnings per share. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Leerink Partners reduced their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. KeyCorp lowered their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Finally, Morgan Stanley cut their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $8.20.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.